



## Announcement Summary

**Entity name**

PATRYS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

1/11/2021

**The Proposed issue is:** A standard pro rata issue (including non-renounceable or renounceable) A placement or other type of issue**Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)**

ASX +security code	+Security description	Maximum Number of +securities to be issued
PAB	ORDINARY FULLY PAID	152,384,608

**Ex date**

3/11/2021

**+Record date**

4/11/2021

**Offer closing date**

29/11/2021

**Issue date**

6/12/2021

**Total number of +securities proposed to be issued for a placement or other type of issue**

ASX +security code	+Security description	Maximum Number of +securities to be issued
PAB	ORDINARY FULLY PAID	75,714,285

**Proposed +issue date**

8/11/2021

Refer to next page for full details of the announcement





## Part 1 - Entity and announcement details

---

### 1.1 Name of +Entity

PATRY'S LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

### 1.2 Registered Number Type

ABN

### Registration Number

97123055363

### 1.3 ASX issuer code

PAB

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

1/11/2021

### 1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

A placement or other type of issue

### 1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

**3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?**

No

Part 3B - Offer details

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +security code and description**

PAB : ORDINARY FULLY PAID

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

**If the entity has quoted company options, do the terms entitle option holders to participate on exercise?**

Yes

Details of +securities proposed to be issued

**ASX +security code and description**

PAB : ORDINARY FULLY PAID

**ISIN Code (if Issuer is a foreign company and +securities are non CDIs)**

**ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities are non CDIs)**

**Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)**

**The quantity of additional +securities to be issued**

1

**For a given quantity of +securities held**

12



**What will be done with fractional entitlements?**

Fractions rounded up to the next whole number

**Maximum number of +securities proposed to be issued (subject to rounding)**

152,384,608

**Offer price details for retail security holders**

**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security for the retail offer?**

AUD 0.03500

**Oversubscription & Scale back details**

**Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?**

Yes

**Describe the limits on over-subscription**

Eligible Shareholders (other than Directors and related parties of the Company) who fully subscribe for their entire Entitlement under the Offer may, in addition to taking up their Entitlements in full, apply for any number of Additional Shares in excess of their Entitlements by using the Top-Up Facility.

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

The Company reserves the right to scale back any applications for Additional Securities in its absolute discretion.

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Details of company options where holders entitled to participate in the offer

---

**ASX +security code and description**

PABO : OPTION EXPIRING 05-AUG-2023

**Date Option must be exercised by**

3/11/2021

---



**ASX +security code and description**

PABOA : OPTION EXPIRING 15-DEC-2023

**Date Option must be exercised by**

3/11/2021

---

---

Part 3C - Timetable

---

**3C.1 +Record date**

4/11/2021

**3C.2 Ex date**

3/11/2021

**3C.4 Record date**

4/11/2021

**3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue**

9/11/2021

**3C.6 Offer closing date**

29/11/2021

**3C.7 Last day to extend the offer closing date**

24/11/2021

**3C.9 Trading in new +securities commences on a deferred settlement basis**

30/11/2021

**3C.11 +Issue date and last day for entity to announce results of +pro rata issue**

6/12/2021

**3C.12 Date trading starts on a normal T+2 basis**

7/12/2021

**3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis**

9/12/2021



Part 3E - Fees and expenses

**3E.1 Will there be a lead manager or broker to the proposed offer?**

Yes

**3E.1a Who is the lead manager/broker?**

Lazarus Corporate Finance Pty Ltd is the Lead Manager and Underwriter

**3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

- a management fee of 1% of the underwritten amount, excluding any amounts received from each Director of the Company and their related entities and excluding all amounts subscribed by Territory Funds Management Pty Ltd pursuant to the Offer  
- a underwriting fee of 5% of the underwritten amount, excluding any amounts received from each Director of the Company and their related entities and excluding all amounts subscribed by Territory Funds Management Pty Ltd pursuant to the Offer

**3E.2 Is the proposed offer to be underwritten?**

Yes

**3E.2a Who are the underwriter(s)?**

Lazarus Corporate Finance Pty Ltd

**3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?**

Fully Underwritten

**3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?**

See above response to question 3E.1b

**3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated**

The termination events, which are circumstances typically found in agreements of this nature, include, without limitation:  
(a) the S&P ASX 200 or S&P ASX 300 Index closes on any 2 consecutive Business Days from the date of this Agreement at a level that is 10% or more below the level of the Index at the close of trading on the Business Day before the date of the Underwriting Agreement;  
(b) the Company is prevented from allotting and issuing the Underwritten Securities within the time required by the Timetable, Listing Rules or applicable laws; and  
(c) default or breach by the Company under the Underwriting Agreement or any representation, warranty or undertaking given by the Company in the Underwriting Agreement or the Offer Materials is or becomes misleading, untrue or incorrect in a material respect.  
Refer to the Entitlement Offer document to be lodged on 9 November 2021, for details on significant events that could lead to the underwriting agreement being terminated.

**3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?**

No

**3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**



Part 3F - Further Information

---

**3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

To support the accelerated development of PAT-DX3, development and partnering opportunities, further research on a PAT-DX3 antibody drug conjugate, funding operations, offer costs, working capital, and other business development and corporate activities.

**3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?**

No

**3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?**

No

**3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue**

Shareholders who do not have a registered address in Australia or New Zealand are not eligible to participate in the Offer.

**3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities**

No

**3F.6 URL on the entity's website where investors can download information about the proposed issue**

[www.patrys.com](http://www.patrys.com)

**3F.7 Any other information the entity wishes to provide about the proposed issue**

**3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?**

No

**3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)





Part 7 - Details of proposed placement or other issue

---

Part 7A - Conditions

---

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?**

No

Part 7B - Issue details

---

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**  
 Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**  
 No

Details of +securities proposed to be issued

---

**ASX +security code and description**

PAB : ORDINARY FULLY PAID

**Number of +securities proposed to be issued**

75,714,285

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?**

AUD - Australian Dollar

**What is the issue price per +security?**

AUD 0.03500

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Part 7C - Timetable

---

**7C.1 Proposed +issue date**

8/11/2021

Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

No

**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

71,428,571 Placement shares  
4,285,714 Commitment fee shares

**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

Yes

**7E.1a Who is the lead manager/broker?**

Territory Funds Management Pty Ltd or its nominee

**7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

- a Commitment fee of 6% payable in Shares (4,285,714 shares)

**7E.2 Is the proposed issue to be underwritten?**

No



**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

To support the accelerated development of PAT-DX3, development and partnering opportunities, further research on a PAT-DX3 antibody drug conjugate, funding operations, offer costs, working capital, and other business development and corporate activities.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

**7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)